Oxford BioDynamics PLC announces that all resolutions proposed at the general meeting of the Company were duly passed. Application has been made for new Ordinary Shares to be admitted to trading on the AIM market of the London Stock Exchange. VCT/EIS Admission is expected to take place on August 21, 2023, and General Admission is expected to take place on August 22, 2023. Following these admissions, the Company's issued ordinary share capital and total voting rights will consist of 169,169,648 Ordinary Shares and 202,303,415 Ordinary Shares, respectively.
In addition, Dr Alexandre Akoulitchev, Chief Scientific Officer, and Paul Stockdale, Chief Financial Officer, subscribed for shares in the PrimaryBid Offer. The independent directors of the Company consider the terms of their subscriptions to be fair and reasonable. The total New Ordinary Shares subscribed for by the Directors and PDMRs participating in the Fundraising are also disclosed.
Furthermore, details of Director/PDMR dealings are provided, including the purchase of Ordinary Shares by Matthew Wakefield and Dr Jon Burrows.